Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00287651 · ClinicalTrials.gov registry record · Phase 2

Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus

A Phase 2 study, sponsored by Florida Atlantic University.

Terminated
Registry status
Phase 2
Development phase
150
Enrollment target

NCT00287651 is a Phase 2 study that was terminated before completion, run by Florida Atlantic University. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00287651, a Phase 2 study, was terminated before completion, sponsored by Florida Atlantic University.

TERMINATED
Registry status
Phase 2
Development phase
150 participants
Enrollment target

Study Summary

Diabetic Retinopathy is the leading cause of blindness in the world. Previous studies have documented beneficial effects of physiologic administration of pulsatile insulin on a variety of diabetic complications such as nephropathy, hypertension, glycemic control, etc. Similar pathogenetic mechanisms have been postulated for diabetic retinal disease. This study examines the effect of pulsatile insulin on patients with varying stages of diabetic retinal disease.

Interventions

  • PROCEDURE Pulsatile IV Insulin
  • PROCEDURE Effects of Pulsatile IV Insulin on Diabetic Retinopathy

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2005-11
Est. Completion 2009-08
Phase Phase 2

Sponsor

Florida Atlantic University

27 total trials

What the Registry Record Tells You About NCT00287651

The ClinicalTrials.gov registry entry for NCT00287651 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Florida Atlantic University, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Pulsatile IV Insulin is the first listed.

NCT00287651 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00287651 about?

NCT00287651 is a clinical study titled "Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus". Diabetic Retinopathy is the leading cause of blindness in the world. Previous studies have documented beneficial effects of physiologic administration of pulsatile insulin on a variety of diabetic complications such as nephropathy, hypertension, glycemic control, etc. Similar pathogenetic mechanisms...

What is the current status of trial NCT00287651?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-11. Estimated completion is 2009-08.

What interventions are being tested in trial NCT00287651?

The interventions under investigation include: Pulsatile IV Insulin (PROCEDURE), Effects of Pulsatile IV Insulin on Diabetic Retinopathy (PROCEDURE).

Who is sponsoring clinical trial NCT00287651?

This trial is sponsored by Florida Atlantic University, which has 27 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.